
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Evotec SE ADR (EVO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EVO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5.74
1 Year Target Price $5.74
1 | Strong Buy |
3 | Buy |
1 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.35% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.36B USD | Price to earnings Ratio - | 1Y Target Price 5.74 |
Price to earnings Ratio - | 1Y Target Price 5.74 | ||
Volume (30-day avg) 6 | Beta 1.1 | 52 Weeks Range 2.84 - 5.64 | Updated Date 08/15/2025 |
52 Weeks Range 2.84 - 5.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.0667 | Actual -0.12 |
Profitability
Profit Margin -20.01% | Operating Margin (TTM) -16.7% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -16.75% |
Valuation
Trailing PE - | Forward PE 59.88 | Enterprise Value 1045219684 | Price to Sales(TTM) 1.75 |
Enterprise Value 1045219684 | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA -21.37 | Shares Outstanding 355198016 | Shares Floating 130516727 |
Shares Outstanding 355198016 | Shares Floating 130516727 | ||
Percent Insiders - | Percent Institutions 2.74 |
Upturn AI SWOT
Evotec SE ADR
Company Overview
History and Background
Evotec SE was founded in 1993 in Hamburg, Germany. Initially focused on drug discovery technologies, it evolved into a fully integrated drug discovery and development company, offering services and solutions across the drug discovery value chain. The ADR allows US investors to invest in Evotec.
Core Business Areas
- EVT Execute: Provides comprehensive drug discovery solutions, including target identification, assay development, high-throughput screening, lead optimization, and pre-clinical development.
- EVT Innovate: Focuses on proprietary drug discovery programs, often through collaborations with pharmaceutical companies, biotech companies, and academic institutions, targeting areas with unmet medical needs.
- Just - Evotec Biologics: Offers development, manufacturing, and formulation services for biologics.
Leadership and Structure
Dr. Werner Lanthaler is the CEO. The company has a supervisory board and an executive management board. It operates with a decentralized structure, with various sites specializing in different aspects of drug discovery and development.
Top Products and Market Share
Key Offerings
- Drug Discovery Services: Provides comprehensive services for drug discovery, including target identification, hit-to-lead optimization, and preclinical development. Market share data is fragmented across various service segments, making a precise overall figure unavailable. Competitors include Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp Drug Development (LH).
- Biologics Development and Manufacturing: Offers services for the development and manufacturing of biologics, including antibodies, proteins, and cell therapies. Market share in this segment is also complex, with significant competition. Competitors include Lonza (LONN.SW), Thermo Fisher Scientific (TMO), and Catalent (CTLT).
Market Dynamics
Industry Overview
The drug discovery services industry is experiencing strong growth, driven by increasing R&D spending by pharmaceutical and biotech companies, the rising complexity of drug targets, and the growing demand for outsourced research services. Biologics development and manufacturing is also rapidly growing.
Positioning
Evotec is a well-positioned player in the drug discovery services market, with a strong reputation for innovation and scientific expertise. It has established partnerships with numerous leading pharmaceutical and biotech companies. Its competitive advantages include its integrated service offerings, its focus on innovation, and its global presence.
Total Addressable Market (TAM)
The global drug discovery market size is projected to reach $107.7 billion by 2030. Evotec is positioned to capture a significant share of this expanding market through its comprehensive service offerings and strategic partnerships. The Biologics TAM is also significant and growing rapidly.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise
- Integrated service offerings
- Established partnerships with leading pharmaceutical and biotech companies
- Global presence
- Strong track record of innovation
Weaknesses
- Dependence on R&D spending by pharmaceutical and biotech companies
- Exposure to competition from other CROs and CDMOs
- Complexity of managing a global organization
- Impact of macroeconomic events
Opportunities
- Increasing demand for outsourced drug discovery services
- Growing adoption of new technologies, such as artificial intelligence and machine learning
- Expanding into new therapeutic areas
- Growth in emerging markets
Threats
- Economic downturns that reduce R&D spending
- Increased competition from other CROs and CDMOs
- Regulatory changes that impact drug development
- Intellectual property risks
Competitors and Market Share
Key Competitors
- Charles River Laboratories (CRL)
- WuXi AppTec (WX)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Evotec possesses a strong integrated platform. However, it faces competition from larger CROs with broader service offerings and geographic reach. Its focus on innovation and strategic partnerships helps it to differentiate itself.
Major Acquisitions
Just Biotherapeutics
- Year: 2019
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expanded Evotec's capabilities in biologics drug discovery and development.
Growth Trajectory and Initiatives
Historical Growth: Evotec has experienced strong revenue growth in recent years, driven by increasing demand for its drug discovery services and its strategic acquisitions.
Future Projections: Analysts project continued revenue growth for Evotec, driven by its strong market position and its investments in new technologies.
Recent Initiatives: Recent initiatives include expanding its genomics capabilities, growing its Just-Evotec Biologics capabilities and strategic partnerships.
Summary
Evotec is a well-positioned drug discovery and development company with strong scientific expertise and integrated service offerings. While it faces competition, its focus on innovation and strategic partnerships provides a competitive edge. Its growth trajectory is promising, driven by increasing demand for outsourced research services. Macro-economic events and R&D funding levels will be key to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available industry reports and estimates. Financial data is subject to change and should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evotec SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-12-04 | CEO & Management Board Member Dr. Christian Wojczewski Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 4740 | Website https://www.evotec.com |
Full time employees 4740 | Website https://www.evotec.com |
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.